Core Insights - Progyny's CEO, Pete Anevski, discussed utilization trends and forecasting during a fireside chat, emphasizing the importance of actual benefit use over eligibility counts [4][2] - The company is launching a new fully insured product, Progyny Select, aimed at small group employers, with expectations to go live in 2027 [6][12] Utilization Trends - Anevski highlighted that utilization rates have remained stable historically, ranging from approximately 1.03% to 1.09%, and emphasized that the company focuses on actual benefit usage rather than fluctuating eligibility counts [2][7] - The first quarter typically sees the highest proportion of individuals beginning their fertility journey, with treatment activity often occurring in subsequent quarters [5][1] Forecasting Methodology - Progyny utilizes client history, industry patterns, and member journey signals to predict utilization, with Q1 consultations leading to higher-revenue treatments in Q2 through Q4 [5][8] - The company acknowledges that 2024 may present unique challenges, including a mid-year dip in utilization influenced by the political environment [10] Progyny Select Rollout - The fully insured small-group product will be marketed through brokers and PEOs, with a focus on signing distributors and training brokers ahead of the critical fourth-quarter renewal season [11][12] - The product is designed with risk management features, including IVF-only coverage and lifetime caps, to control utilization risk [6][14] Competitive Landscape - Anevski noted that the recent selling season did not feel more competitive than previous years, with Progyny continuing to win the majority of contracts against competitors [19] - Some competitors have faced challenges, including bankruptcy, which has created opportunities for Progyny to strengthen its market position [19] Technology Investments - Progyny is investing in AI and data technology to enhance services for stakeholders, aiming to reduce friction for patients and improve operational efficiency [17][18] - The company believes that technology can support provider partnerships and potentially lower costs, thereby enhancing its negotiating position [18]

Summary of Progyny Conference Call Company Overview - **Company**: Progyny - **Industry**: Fertility and IVF Benefits - **Position**: One of the largest publicly traded fertility IVF benefit partners Key Points and Arguments Financial Performance - **Fourth Quarter Earnings**: Noted a reduction of 400,000 eligible lives due to administrative corrections from employer clients [1][2] - **Utilization Rate**: Maintained a tight range of 1.03 to 1.09 over the years, focusing on actual utilization rather than just eligible lives [3][4] - **Attrition**: Primarily from lower-utilizing clients, while new sign-ons from the selling season are expected to be better utilizers [5][6] Utilization Trends - **Utilization Timing**: New cohorts typically start utilizing benefits in Q2 through Q4 after initial consultations in Q1 [16][17] - **Consultation to Treatment Cycle**: Average of 1.8 retrievals per live birth, indicating multiple cycles may occur before a transfer [17][18] Progyny Select Program - **Launch Strategy**: The fully insured program is set to go live in 2027, with current efforts focused on signing up distributors and training brokers [23][29] - **Sales Model**: Commission-based structure minimizes upfront expenses, with revenue tied to client renewals [30][32] - **Risk Mitigation**: Designed to address small group employers, with underwriting based on extensive data from smaller clients [35][37] Market Opportunities and Challenges - **State Mandates**: California's IVF mandate could significantly increase volumes, but competition remains a challenge [48][50] - **Education and Awareness**: Emphasis on educating brokers and distribution partners about the benefits of Progyny's offerings [51][52] Competitive Landscape - **Market Position**: Despite competition, Progyny continues to win the majority of clients, with some competitors facing financial challenges [80][81] - **Investment in Offerings**: Ongoing investments to enhance services and maintain a competitive edge [81] Technology and Data Utilization - **AI and Data Integration**: Investments in technology aim to improve client experiences and outcomes by automating tasks and providing better recommendations [75][78] Progyny Rx - **Patient Assistance Program**: Progyny Rx is not designed for those with coverage, focusing instead on those without insurance [60][62][70] - **Impact on Business**: No expected impact on Progyny's business from the Progyny Rx program as it serves a different market segment [73] Additional Important Insights - **Retention Rates**: High retention rates (99%) attributed to comprehensive program management for clients [42] - **Market Dynamics**: The competitive environment remains stable, with no significant increase in competition noted [81] This summary encapsulates the key discussions and insights from the conference call, highlighting Progyny's strategic focus, market positioning, and operational dynamics.

Group 1 - The company experienced strength in Q4, exceeding guidance with stable utilization rates [2] - Membership growth was highlighted, with a reported increase of approximately 20% in 2025, excluding one customer [2] - The CEO provided insights into the overall business performance and key highlights during the quarter [2]

Summary of Progyny FY Conference Call (March 11, 2026) Company Overview - **Company**: Progyny (NasdaqGS: PGNY) - **Industry**: Fertility Benefits and Assisted Reproductive Technology Key Points Financial Performance - **4Q Performance**: Progyny exceeded guidance with a growth of approximately 20% in 2025, excluding one customer [1] - **Client Retention**: The company achieved a 99% client retention rate, with about 30% of clients expanding their benefits [2] - **Revenue Guidance**: The company has guided for a revenue growth of about 7% for the year, aligned with membership growth [34] Membership and Utilization - **Membership Estimate**: The estimated number of lives for 2026 was revised to 7.2 million, attributed to administrative updates rather than layoffs or macroeconomic factors [3] - **Utilization Rate**: The historical utilization rate has been consistent, ending last year at 1.04%. The company expects to remain within the low to middle of its historical utilization range for the current year [8] - **Impact of Macroeconomic Factors**: Utilization is primarily driven by the biological need for fertility assistance rather than macroeconomic conditions, such as tax refunds [10][11] Competitive Landscape - **Market Position**: Progyny competes more with managed care organizations (MCOs) that offer fertility benefits rather than standalone competitors. The company maintains a high win rate when clients decide to add fertility benefits [13][17] - **MCO Engagement**: MCOs have not become more aggressive in the fertility space due to lack of financial incentives, as they do not profit from increased utilization of fertility benefits [18][19] Product Expansion and Opportunities - **Client Expansion**: 30% of clients added to their offerings, including cycles and new products like menopause and postpartum support [20][22] - **Fully Insured Market**: Progyny is expanding into the fully insured market, addressing the needs of small employers who typically lack access to fertility benefits [24][25] - **Sales Cycle**: The sales cycle for fully insured buyers aligns with traditional cycles, with renewals generally occurring in the fourth quarter [28] Risk Management - **Contract Duration**: Fully insured buyers operate on annual contracts, allowing for premium adjustments based on experience [31] - **Utilization Risk**: Initial utilization risk exists with smaller populations, but as the risk pool grows, it will be managed similarly to self-insured populations [32] Future Outlook - **Growth Expectations**: The company expects to add approximately 1 million lives annually, with potential incremental contributions from new products [42] - **Long-term Margin Opportunities**: Future margin expansion is anticipated as investments taper off and operational efficiencies improve, particularly through AI and care management enhancements [39][40] Additional Insights - **Pipeline Status**: The current pipeline is primarily carryover from previous years, with positive expectations for the upcoming sales season [41] - **Market Positioning**: Progyny is well-positioned to expand its addressable market and maintain a competitive edge over standalone competitors and MCOs [42] This summary encapsulates the key insights and data points from the Progyny FY Conference Call, highlighting the company's performance, market dynamics, and future strategies.

Company Overview - Hims & Hers Health (HIMS) reported full-year revenue of $2.347 billion, a 59% increase year-over-year, with a subscriber base exceeding 2.5 million and monthly revenue per subscriber at $83 [1][2] - Progyny (PGNY) achieved full-year revenue of $1.289 billion, up 10.4% year-over-year, with record adjusted EBITDA of $222.09 million and no debt [1][2] Analyst Ratings and Price Targets - Barclays raised the price target for Hims & Hers to $29 from $25, maintaining an Overweight rating, following a distribution agreement with Novo Nordisk that alleviated legal concerns [1][2] - Canaccord reduced Progyny's price target to $19 from $26 while keeping a Hold rating, citing cautious guidance for 2026 [1][2] Market Reactions and Performance - Hims & Hers shares surged 48.36% in the week ending March 10 after the Novo deal announcement, with an additional 5.91% increase on the most recent trading day [1][2] - Progyny's shares fell 30.26% year-to-date, trading at $17.91, just above a 52-week low, following weak 2026 guidance [1][2] Growth Projections - Hims & Hers projects 2026 revenue between $2.7 billion and $2.9 billion, with adjusted EBITDA expected to be between $300 million and $375 million [2] - Progyny's 2026 revenue guidance is between $1.355 billion and $1.405 billion, indicating a growth rate of only 5.1% to 9.0%, a significant slowdown from 2025 [2] Strategic Developments - The Novo Nordisk agreement allows Hims to distribute approved Ozempic and Wegovy injectables, which is expected to enhance growth opportunities [1][2] - The departure of Progyny's president at the end of 2025 is a leadership change that investors are monitoring closely [2]

Summary of Progyny (NasdaqGS:PGNY) 2026 Conference Call Company Overview - **Company**: Progyny, a healthcare technology company specializing in fertility benefits and services Key Points Industry Dynamics - **Healthcare Sector Growth**: Progyny has seen a significant increase in healthcare clients, now representing the largest percentage of their industry exposure, driven by the need for fertility support among large hospital systems and healthcare providers [38][44] - **Fertility Support Demand**: The company emphasizes the importance of fertility benefits, especially in industries with a large female workforce, which has led to a competitive advantage in attracting healthcare clients [44][45] Financial Performance - **2025 Utilization Trends**: The company reported improving utilization rates in 2025, with consistent consumption patterns observed throughout the year. Utilization is defined as the number of members engaging with the services [5][6][10] - **Revenue Model**: Progyny operates on a consumption model rather than a per-member-per-month model, meaning revenue is driven by actual service usage rather than membership counts [12][16][24] Membership and Client Dynamics - **Membership Adjustments**: The company has experienced variability in membership counts, which has not negatively impacted revenue due to the nature of their consumption model. They maintain a hands-off approach in addressing discrepancies in client-reported member counts [12][15][24] - **New Client Acquisition**: Approximately 50% of new clients are adopting fertility benefits for the first time, while the other half are transitioning from traditional carrier benefits [46] Product and Service Innovations - **Smart Cycle Utilization**: The Smart Cycle model allows for flexible treatment options, and clients are increasingly opting for more comprehensive coverage, including unlimited Smart Cycles [49] - **New Product Launches**: Progyny has introduced menopause and pregnancy/postpartum products, which have seen positive adoption rates. The company is focused on increasing awareness and utilization of these services [63][64] Technology and AI Integration - **IT Investments**: Progyny is investing in IT systems to enhance member engagement and improve service delivery. The focus is on maintaining a human touch in patient care while leveraging AI for operational efficiencies [51][52][53] - **AI's Role**: The company views AI as a tool for improving business operations rather than replacing human roles, particularly in patient care advocacy [51][53] Future Outlook - **Progyny Select Launch**: The new Progyny Select product aims to provide fertility benefits to smaller companies, with positive feedback from initial market testing. The company is cautious about setting expectations for its first year [72][74] - **Risk Management**: The company has designed the Progyny Select product to mitigate risks associated with underwriting, including fixed Smart Cycle limits and a risk premium in pricing [78][82] Financial Strategy - **Share Buyback Program**: Progyny is actively engaged in a share buyback program, with a focus on returning capital to shareholders while managing growth and operational needs [91][92] Additional Insights - **Pharmacy Management**: The company emphasizes the importance of managing drug costs and usage effectively, highlighting the potential for significant savings through their holistic approach to fertility services [87][88] This summary encapsulates the key insights and strategic directions discussed during the Progyny conference call, reflecting the company's focus on growth, innovation, and client satisfaction in the fertility benefits sector.

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. At the Leerink Partners Global Healthcare Conference, Mark Livingston, Chief Financial Officer, wi ...

Pan Research is an independent research platform focused on uncovering under-followed micro-caps (sub-$500M market cap), small-caps (below $2B), and selectively mid-caps (below $10B). We concentrate on businesses exhibiting improving fundamentals, operating leverage, and potential valuation dislocations. Our approach is research-driven, industry-agnostic, and focused on identifying companies where fundamentals and market perception may diverge. Our work typically develops 12-18 month fundamental theses cent ...

Client Base and Market Expansion - The company has expanded its client base to over 590 employers, covering approximately 7.2 million employees and their dependents[26] - The addressable market for women's health and family building benefits in the U.S. is estimated to represent approximately 106 million potential covered lives, with the company's current member base being a mid-single digit percent of this total market opportunity[29] - The company plans to expand its addressable market to include large group fully insured employers, capitalizing on the rising demand for women's health solutions[30] - Progyny aims to expand its client base by leveraging relationships with benefits consultants and targeting self-insured employers[52] - The company expects to see growth from existing clients adding incremental services to their fertility benefits program[54] - The sales team added over 70 new clients in 2025, with many current clients switching from prior fertility benefits to Progyny[61] - The company currently serves over 590 employers across more than 40 industries, representing approximately 7.2 million lives under contract[56] Product Offerings and Solutions - The company offers 20 different Smart Cycle treatment bundles designed to provide comprehensive fertility treatment, which have resulted in higher rates of pregnancy and live births, as well as lower miscarriage rates[32] - The pregnancy and postpartum solution aims to improve outcomes and reduce complications through personalized clinical guidance and support[36] - The menopause and midlife solution provides access to specialized clinical coaching and a curated network of providers to enhance health outcomes[37] - Progyny Rx, the integrated pharmacy benefits solution, streamlines medication management and reduces dispensing and delivery time, which is critical for the success of fertility treatments[35] Clinical Outcomes and Quality - Progyny's in-network average live birth rate per attempted retrieval is 46.7%, significantly higher than the national average of 36.8%[48] - The single embryo transfer rate for Progyny members is 96.6%, compared to 78.9% for all provider clinics[48] - The company emphasizes the importance of maintaining a high-quality network of fertility specialists to ensure optimal clinical outcomes and member satisfaction[34] - 92% of clients under contract are utilizing the Progyny Rx solution, including 97% of clients signed in fiscal year 2025[54] Financial Performance and Stability - As of December 31, 2025, the company had cash and cash equivalents of $112.2 million and marketable securities of $197.9 million[293] - The company does not enter into investments for trading or speculative purposes and has not used any derivative financial instruments to manage interest rate risk exposure[293] - A hypothetical 1% change in interest rates would not result in a material impact on the company's consolidated financial statements[293] - The company believes that inflation has not had a material effect on its business, financial condition, or results of operations[294] - The company is positioned to realize organic revenue growth as clients and their employee bases grow and utilize more services[53] Compliance and Regulatory Matters - The company is required to maintain TPA and/or PBM licenses and registrations in certain jurisdictions[64] - The company is subject to certain provisions of ERISA in its capacity as a TPA and/or PBM for clients[65] - The company has structured its operations to comply with state corporate practice and fee-splitting prohibitions[73] Company Culture and Workforce - As of December 31, 2025, the company had 856 employees, with a focus on culture, engagement, and competitive compensation[77] - The company experiences moderate seasonality in revenue, with a higher proportion of revenue in the second half of the year[75] Intellectual Property - The company has a number of registered trademarks, including Progyny, Smart Cycle, and UnPack It, with no known rights of third parties affecting them[74]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Neurogene Inc. (NGNE) is up 34% at $26.42 [3] - Cardio Diagnostics Holdings, Inc. (CDIO) is up 20% at $6.29 [3] - Applied Optoelectronics, Inc. (AAOI) is up 19% at $64.00 [3] - Caris Life Sciences, Inc. (CAI) is up 19% at $22.93 [3] - Block, Inc. (XYZ) is up 18% at $64.59 [3] - MARA Holdings, Inc. (MARA) is up 16% at $9.84 [3] - NCR Atleos Corporation (NATL) is up 14% at $48.13 [3] - Birchtech Corp. (BCHT) is up 12% at $2.70 [3] - The RealReal, Inc. (REAL) is up 11% at $13.80 [3] - Candel Therapeutics, Inc. (CADL) is up 10% at $5.68 [3] Premarket Losers - Duolingo, Inc. (DUOL) is down 24% at $88.30 [4] - Xponential Fitness, Inc. (XPOF) is down 23% at $6.16 [4] - Emergent BioSolutions Inc. (EBS) is down 22% at $8.58 [4] - Flutter Entertainment plc (FLUT) is down 14% at $105.85 [4] - Ginkgo Bioworks Holdings, Inc. (DNA) is down 14% at $8.27 [4] - Willdan Group, Inc. (WLDN) is down 12% at $104.63 [4] - Duos Technologies Group, Inc. (DUOT) is down 12% at $7.67 [4] - CoreWeave, Inc. (CRWV) is down 11% at $85.96 [4] - Zscaler, Inc. (ZS) is down 9% at $152.22 [4] - Progyny, Inc. (PGNY) is down 8% at $20.40 [4]